Wednesday, July 26, 2017

Diplomat Now Dispensing VOSEVI™ to Treat Chronic Hepatitis C Virus

The nation's largest independent specialty pharmacy is now dispensing VOSEVI™ (sofosbuvir, velpatasvir, and voxilaprevir)

FLINT, Mich., July 26, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. is now dispensing newly approved VOSEVI™ (sofosbuvir/velpatasvir/voxilaprevir) to treat hepatitis C virus infection

VOSEVI is used to treat all genotypes of chronic hepatitis C virus infection. It is indicated for adults without cirrhosis (liver disease) or with compensated cirrhosis who have previously been treated with a regimen containing an NS5A inhibitor such as EPCLUSA® (sofosbuvir/velpatasvir); HARVONI® (ledipasvir/sofosbuvir); VIEKIRA PAK™ or VIEKIRA XR™ (dasabuvir/ombitasvir/paritaprevir/ritonavir); TECHNIVIE™ (ombitasvir/paritaprevir/ritonavir); ZEPATIER® (elbasvir/grazoprevir); or DAKLINZA™ (daclatasvir).

VOSEVI is also indicated for chronic hepatitis C infection with genotype 1a or 3 and previous treatment with a regimen containing SOVALDI® (sofosbuvir) without an NS5A inhibitor.

To learn more about Diplomat's hepatitis program, visit

VOSEVI is a fixed-dose, combination tablet administered once-daily with food for 12 weeks. It contains sofosbuvir and velpatasvir­, as well as the newly approved voxilaprevir.

"Diplomat is proud to expand its therapy offerings to patients who have been diagnosed with chronic hepatitis C," said Paul Urick, president of Diplomat. "Providing an opportunity to treat patients who have failed current treatment options, this combination tablet is a valuable addition to our product offering."

More than 2.7 million Americans have hepatitis C, according to the Centers for Disease Control and Prevention. Hepatitis C infection becomes chronic in approximately 75–85 percent of cases. Unlike many serious diseases, hepatitis C can be cured with treatment.

Hepatitis C causes liver inflammation. Some people with chronic hepatitis C infection develop cirrhosis, in which liver tissue is replaced by scar tissue, eventually preventing the liver from functioning properly.

VOSEVI is manufactured by Gilead Sciences, Inc. For full prescribing information, click here.

No comments:

Post a Comment